Form 424B5 Tonix Pharmaceuticals
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-254975
Registration No. 333-251500
Registration No. 333-237610
(To Prospectus Dated May 5, 2021, January 4, 2021 and April 17, 2020)
This prospectus supplement amends and supplements the information in the prospectus, dated April 8, 2020, filed as a part of our registration statement on Form S-3 (File No. 333-237610), as previously supplemented by our prospectus supplements dated April 8, 2020, September 4, 2020, or the 2020 Prospectus, the information in the prospectus, dated January 4, 2021, filed as part of our registration statement on Form S-3 (File No. 333-251500), as previously supplemented by our prospectus supplement dated April 16, 2021, together with the 2020 Prospectus, the 2020/2021 Prospectuses, the prospectus, dated May 5, 2021, filed as a part of our registration statement on Form S-3 (File No. 333-254975), as previously supplemented by our prospectus supplement dated December 29, 2021, and together with the 2020/2021 Prospectuses, the Prior Prospectuses. This prospectus supplement should be read in conjunction with the Prior Prospectuses, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectuses. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectuses, and any future amendments or supplements thereto.
Under the Prior Prospectuses, we collectively registered up to $240,000,000 of our Common Stock, $0.001 par value per share, for offer and sale pursuant to a Sales Agreement, dated April 8, 2020, or the Sales Agreement, between us and A.G.P./Alliance Global Partners. From April 8, 2020 through the date of this prospectus supplement, we sold an aggregate of 31.2 million shares of our Common Stock for an aggregate purchase price of $212.8 million under the Prior Prospectuses. As of the date of this prospectus supplement, we are increasing the aggregate amount of Common Stock that we are offering pursuant to the Sales Agreement, such that we are offering up to an aggregate of $320,000,000 of our Common Stock for sale under the Sales Agreement, including the shares of Common Stock previously sold, or $107.2 million from and after the date hereof.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is August 9, 2022.
- U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.54%
- Micron Technology (MU) Shares Decline After Revenue, Guidance Misses Expectations
- Nike Shares Down 2% Despite Better Than Expected Q1 Results
- Apple (AAPL) Extends Decline as BofA Downgrades to Neutral on More Balanced Risk/Reward
- Meta Platforms (META) to Freeze Hiring and Restructure Teams - Bloomberg
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tonix Pharma (TNXP) PT Lowered to $6.50 at Noble Capital
- Kitron: Ferroamp signs production agreement with Kitron
- New to The Street TV / Newsmax TV Announces Its Corporate Interviews on Episode #389, Airing Sunday, September 25, 2022, 10-11 AM ET
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!